Biosimilars of basiliximab

Biosimilars/General | Posted 26/08/2016 post-comment0 Post your comment

Basiliximab is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is an immunosuppresant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.

Transplant1 AA010155 V13E31

The originator product, Novartis’s Simulect (basiliximab), was approved by the US Food and Drug Administration (FDA) on 12 May 1998 and by the European Medicines Agency (EMA) on 9 October 1998 [1]. Simulect had worldwide sales of US$1.1 billion in 2015.

The patents on Simulect expired in Canada in March 2011 and in Europe in April 2013 [1]. To our knowledge, there is only one basiliximab non-originator biological* currently in development, see Table 1.

Table 1: Non-originator biological* of basiliximab in development

Company name, Country Product name Stage of development
Sorrento Therapeutics/MabTech, USA/China* STI-003 Working on copy biological in China [2]
*See editor’s comment

US-based biopharmaceutical company Sorrento Therapeutics (Sorrento) and partner, MabTech, are working on STI-003 in China, a copy biological for basiliximab (Simulect) [2].

Editor’s comment
It should be noted that ‘copy biologicals’ approved in China might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related articles
Biosimilars of omalizumab

Biosimilars of tocilizumab

Biosimilars of eculizumab

Biosimilars of ranibizumab

Biosimilars of rituximab

1. Derbyshire M. Patent expiry dates for best-selling biologicals, Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(4):178-9. doi:10.5639/gabij.2015.0404.040
2. GaBI Online - Generics and Biosimilars Initiative. Positive phase III results for omalizumab copy biological []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 26]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

comment icon Comments (0)
Post your comment
Related content
CVS’ Cordavis to launch Sandoz’s Hyrimoz (adalimumab)
15 AA010699
Biosimilars/General Posted 03/10/2023
Proposal to widen access to trastuzumab in New Zealand
113 MD002138
Biosimilars/General Posted 28/07/2023
GADECCU position statement on biosimilars updated
136 AA011035
Biosimilars/General Posted 14/07/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010